The brief

Analyst view

• AbbVie generates $61 billion annual revenue and is known for Humira and Botox.
• Chairman and CEO Robert Michael has led the company since July 2024, with board promotion in March 2026.
• Capstan acquisition in June 2025 brought CPTX2309, an in vivo CAR-T therapy in Phase 1 trials for B cell-mediated autoimmune diseases.

Technical approach

As reported

In vivo CAR-T

Cell engineering in the bloodstream

CPTX2309 delivers CAR mRNA directly to CD8+ T cells, avoiding ex vivo manufacturing and lymphodepleting chemotherapy.

B cell reset

Immune system reprogramming

Transient anti-CD19 CAR expression depletes autoreactive B cells while allowing healthy populations to regenerate, resetting tolerance.

Autoimmune focus

Treatment of B cell-mediated disease

Initial indications focus on autoimmune diseases driven by B cells, such as lupus, rheumatoid arthritis variants, and vasculitis.